Kura Oncology, Inc. (KURA)
NASDAQ: KURA · Real-Time Price · USD
9.39
+0.43 (4.80%)
At close: Mar 9, 2026, 4:00 PM EDT
9.35
-0.04 (-0.43%)
After-hours: Mar 9, 2026, 7:56 PM EDT
Kura Oncology Revenue
In the year 2025, Kura Oncology had annual revenue of $67.48M with 25.24% growth. Kura Oncology had revenue of $17.34M in the quarter ending December 31, 2025, a decrease of -67.83%.
Revenue (ttm)
$67.48M
Revenue Growth
+25.24%
P/S Ratio
12.29
Revenue / Employee
$351,469
Employees
192
Market Cap
829.42M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| MannKind | 348.97M |
| Arvinas | 262.60M |
| Xencor | 125.58M |
| CytomX Therapeutics | 113.63M |
| Janux Therapeutics | 10.00M |
KURA News
- 3 days ago - Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 days ago - Kura Oncology, Inc. (KURA) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 4 days ago - Kura Oncology Reports Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 11 days ago - Kura Oncology to Report Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 12 days ago - Kura Oncology to Participate in Three Upcoming Investor Conferences - GlobeNewsWire
- 6 weeks ago - Kura Oncology: Safety Profile Of Komzifti Supports My Upgrade To Strong Buy - Seeking Alpha
- 2 months ago - Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones - GlobeNewsWire
- 3 months ago - Kura Oncology, Inc. (KURA) Discusses Ziftomenib Combination Data in Newly Diagnosed and Relapsed/Refractory NPM1-m and KMT2A-r AML Transcript - Seeking Alpha